Marinomed

About:

Marinomed is a biopharmaceutical company that develops innovative anti-viral and immunological treatments.

Website: http://www.marinomed.com

Top Investors: Nice & Green SA, Arax Capital Partners, aws Mittelstandsfonds

Description:

Marinomed is a biopharmaceutical development company focusing on the development of innovative therapies based on patent protected technology platforms. Products against respiratory viruses derived from the proprietary MAVIREX platform are marketed with renowned partners in a growing number of countries around the globe. The new MARINOSOLV platform allows novel stable aqueous formulations of hardly soluble compounds such as corticosteroids, enabling a faster onset of action and a better bioavailability. The MARINOSOLV technology is not limited to a specific compound and has the potential to facilitate delivery of any compound with solubility issues. Marinomed was founded on 2006 and is headquartered in Vienna, Austria.

Total Funding Amount:

$6.96M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Vienna, Wien, Austria

Founded Date:

2006-01-01

Contact Email:

office(AT)marinomed.com

Founders:

Andreas Grassauer

Number of Employees:

11-50

Last Funding Date:

2021-10-05

IPO Status:

Private

Industries:

© 2025 bioDAO.ai